LifeMD, Inc. (LFMD) Form 10-Q — Aug 5, 2026
LifeMD's Q2 2026 telehealth revenue fell 4% year-over-year to $47.3 million while its net loss widened roughly sixfold to $7.1 million ($0.16 per share vs $0.05), driven by a 27% jump in selling and marketing spend to $28.0 million. The filing discloses LifeMD was out of compliance with the Consolidated Interest Coverage Ratio covenant on its $30 million Citizens Bank revolving credit facility as of March 31, 2026; a June 30, 2026 waiver and amendment removed that test but added a new covenant requiring cash plus unused availability of at least $40 million beginning with the quarter ended September 30, 2026.
Key figures
- Revenue
- 47281085
- Total Debt
- 0
- Revenue Yoy
- -4% (Q2); -2% (H1 2026: $97,444,041 vs $99,906,781)
- Cash Position
- 25141615
- Shares Outstanding
- 48200837
- Discontinued ops
- WorkSimpli (PDFSimpli) sold to Lion Buyer, LLC on November 4, 2025
- Accumulated deficit
- 246112737
- Stockholders equity
- 7966455
- Credit facility size
- 30000000
- Gross profit q2 2026
- 41996762
- Pharmacy concentration
- three third-party pharmacies supplied 87% of fulfillment as of June 30, 2026
- Preferred dividend rate
- 8.875% of $25.00 liquidation preference ($2.21875/share/year)
- Gross margin pct q2 2026
- 88.82
- Negative working capital
- 4500000
- Active patient subscribers
- 356000
- Atm availability remaining
- 44600000
- Cumulative error adjustment
- 3600000
- Operating cash flow h1 2025
- 11707834
- Quarterly preferred dividend
- 776562
- Selling marketing increase pct
- 27
- Credit facility increase option
- 20000000
- Selling marketing spend q2 2026
- 28035947
- Covenant min cash plus availability
- 40000000
Price after filing
Close on the filing date to close N calendar days later (from $3.90). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.